Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Protein expression"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
Won Hwangbo, Jeong Hyeon Lee, Sangjeong Ahn, Seojin Kim, Kyong Hwa Park, Chul Hwan Kim, Insun Kim
Korean J Pathol. 2013;47(2):107-115.   Published online April 24, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.107
  • 11,684 View
  • 81 Download
  • 14 Crossref
AbstractAbstract PDF
Background

The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment.

Methods

A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification.

Results

EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6- (CK5/6-) group, 11.2% of the HER-2-, EGFR+, CK5/6- group, and 19.1% of the HER-2-, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki-67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6.

Conclusions

EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.

Citations

Citations to this article as recorded by  
  • Identification of a cross-talk between EGFR and Wnt/beta-catenin signaling pathways in HepG2 liver cancer cells
    Gurjinder Singh, Md Mehedi Hossain, Aadil Qadir Bhat, Mir Owais Ayaz, Nasima Bano, Rafiqa Eachkoti, Mohd Jamal Dar
    Cellular Signalling.2021; 79: 109885.     CrossRef
  • Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
    Shailendra K. Gautam, Ranjana K. Kanchan, Jawed A. Siddiqui, Shailendra K. Maurya, Sanchita Rauth, Naveenkumar Perumal, Pranita Atri, Ramakanth C. Venkata, Kavita Mallya, Sameer Mirza, Moorthy P. Ponnusamy, Vimla Band, Sidharth Mahapatra, Maneesh Jain, Su
    Cancers.2020; 12(10): 2838.     CrossRef
  • Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line
    Mona A.M. Abo-Zeid, Mahmoud T. Abo-Elfadl, Amira M. Gamal-Eldeen
    Environmental Toxicology and Pharmacology.2019; 71: 103207.     CrossRef
  • Improved characterization of the relationship between long intergenic non‐coding RNA Linc00152 and the occurrence and development of malignancies
    Jiasheng Xu, Jingjing Guo, Yangkai Jiang, Yujun Liu, Kaili Liao, Zhonghua Fu, Zhenfang Xiong
    Cancer Medicine.2019; 8(10): 4722.     CrossRef
  • Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome
    Ge Yan, Mohamed E.M. Saeed, Sebastian Foersch, Jose Schneider, Wilfried Roth, Thomas Efferth
    Oncotarget.2019; 10(20): 1918.     CrossRef
  • A novel matrine derivative WM622 inhibits hepatocellular carcinoma by inhibiting PI3K/AKT signaling pathways
    Xiao Sun, Xiao-bin Zhuo, Yi-ping Hu, Xuan Zheng, Qing-jie Zhao
    Molecular and Cellular Biochemistry.2018; 449(1-2): 47.     CrossRef
  • lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway
    Yan Zhang, Cheng Xiang, Yuling Wang, Yuanyuan Duan, Ci Liu, Yongli Jin, Yajing Zhang
    Biomedicine & Pharmacotherapy.2017; 94: 644.     CrossRef
  • Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
    Areej Fatima, Fomaz Tariq, Muhammad Faraz Arshad Malik, Muhammad Qasim, Farhan Haq
    Journal of Breast Cancer.2017; 20(3): 246.     CrossRef
  • Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
    Malgorzata Banys-Paluchowski, Isabell Witzel, Sabine Riethdorf, Brigitte Rack, Wolfgang Janni, Peter A. Fasching, Erich-Franz Solomayer, Bahriye Aktas, Sabine Kasimir-Bauer, Klaus Pantel, Tanja Fehm, Volkmar Müller
    Scientific Reports.2017;[Epub]     CrossRef
  • EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib
    James P. De Andrade, Jung M. Park, Vivian W. Gu, George W. Woodfield, Mikhail V. Kulak, Allison W. Lorenzen, Vincent T. Wu, Sarah E. Van Dorin, Philip M. Spanheimer, Ronald J. Weigel
    Molecular Cancer Therapeutics.2016; 15(3): 503.     CrossRef
  • Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
    H J Lee, A N Seo, E J Kim, M H Jang, Y J Kim, J H Kim, S-W Kim, H S Ryu, I A Park, S-A Im, G Gong, K H Jung, H J Kim, S Y Park
    British Journal of Cancer.2015; 112(1): 103.     CrossRef
  • Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma
    GANG LIN, XIAO-JIANG SUN, QIAN-BO HAN, ZHUN WANG, YA-PING XU, JIA-LEI GU, WEI WU, GU ZHANG, JIN-LIN HU, WEN-YONG SUN, WEI-MIN MAO
    Oncology Letters.2015; 10(2): 901.     CrossRef
  • Immunohistochemical Classification of Primary and Secondary Glioblastomas
    Kyu Sang Lee, Gheeyoung Choe, Kyung Han Nam, An Na Seo, Sumi Yun, Kyung Ju Kim, Hwa Jin Cho, Sung Hye Park
    Korean Journal of Pathology.2013; 47(6): 541.     CrossRef
  • A Comparison of Tumor Biology in Primary Ductal CarcinomaIn SituRecurring as Invasive Carcinoma versus a NewIn Situ
    Wenjing Zhou, Christine Johansson, Karin Jirström, Anita Ringberg, Carl Blomqvist, Rose-Marie Amini, Marie-Louise Fjallskog, Fredrik Wärnberg
    International Journal of Breast Cancer.2013; 2013: 1.     CrossRef
p53 Protein Expression in Infiltrating Ductal Carcinoma of the Breast.
Soon Hee Jung, Mee Yon Cho, Soo Yong Kim
Korean J Pathol. 1996;30(1):7-14.
  • 1,638 View
  • 22 Download
AbstractAbstract PDF
Overexpression of the nuclear phosphoprotein p53 is the most common genetic anomaly found in primary human cancer and mutation of the tumor suppressor gene p53 has been identified in breast cancer cell lines. In this study, we evaluated the prognostic significance of p53 protein expression in patients with mammary infiltrating ductal carcinoma and its correlation with histopathologic grade, lymph node status, tumor size, p53 protein expression and survival. Among 53 cases, p53 protein expression was detected in 26(49.1%) cases by immunohistochemistry. There was no correlation between p53 protein overexpression and histopathologic grade(p=0.09) or lymph node status(p=0.38) and between survival and histopathologic grade (p=0.68) or lymph node status(p=0.52). However, p53 protein expression was significantly correlated with survival(p=0.01) and patients with p53 protein-positive tumors showed poorer survival times. But Cox multivariate analysis showed the lymph node status is significant(p=0.01). The authors conclude that the presence of mutant p53 protein and lymph node status may serve a prognostic role, in a subset of mammary infiltrating ductal carcinoma cases.

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP